Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

Primary Brain Neoplasm Clinical Trial

Official title: Hyperpolarized Pyruvate Imaging of Glioma: Imaging-Pathological Correlation

Status Recruiting

Clinical Trial Summary

This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers better diagnose glioma in patients with brain tumors.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To establish a clinical infrastructure for performing hyperpolarized carbon C 13 pyruvate (hyperpolarized 13-C-pyruvate) imaging in the human brain at MD Anderson.

SECONDARY OBJECTIVES:

I. To assess the correlation between conversion rate of hyperpolarized pyruvate to lactate (kpl) values and Ki-67 quantitation in the tumor.

II. To compare kpl values between tumor and normal brain within patient. III. To assess the association between kpl values and pathology results, including conventional, diffusion, perfusion, and permeability imaging.

IV. To assess the association between kpl values and magnetic resonance (MR) imaging findings.

V. To assess the association between kpl values and genomic findings, including methylation, ribonucleic acid [RNA], and deoxyribonucleic acid [DNA]).

OUTLINE:

Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over 10-20 seconds and then undergo an MRSI scan.

After completion of study, patients are followed up for 1 day. ;

Related Conditions & MeSH terms

• Brain Neoplasms
• Primary Brain Neoplasm

• NCT number: NCT03830151
• Study type: Interventional
• Source: M.D. Anderson Cancer Center
• Contact: Dawid Schellingerhout
• Phone: 713-794-5673
• Email: dawid.schellingerhout@mdanderson.org
• Status: Recruiting
• Phase: Phase 1
• Start date: May 16, 2019
• Completion date: December 31, 2025